Potent and selective inhibitor of GSK-3β (IC50=78nM). Stimulates glycogen synthesis in human liver cells and mimics other actions of insulin. Protects primary neurons from death induced by PI-3 kinase pathway inhibition suggesting therapeutic potential in neurodegenerative diseases and stroke.
Product Details
| Formula: | C16H10N3O5Cl |
| |
| MW: | 359.7 |
| |
| CAS: | 264218-23-7 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Identity: | Determined by NMR. |
| |
| Appearance: | Yellow Solid. |
| |
| Solubility: | Soluble in DMSO, ethanol or methanol. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity: A.A. Culbert, et al.; FEBS Lett.
507, 288 (2001),
Abstract;
Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death: D.A.E. Cross, et al.; J. Neurochem.
77, 94 (2001),
Abstract;
Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription: M.P. Coghlan, et al.; Chem. Biol.
7, 793 (2000),
Abstract;
